![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
October 5, 2006
Lilly Ends Development
of Diabetes Drug (PharmaGossip)
A post on this insider blog reports that Eli Lilly has "quietly halted
development of naveglitizar, a new class of diabetes medicine that also has
been abandoned by two other drugmakers because of safety concerns."
"Goodbye and good riddance!" the blogger writes, pointing out that in trials the drug was "associated with various side effects, including liver toxicity, cancer and heart problems."
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct